CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
NMPA OF CHINA GRANTS NDA APPROVAL TO PCV13*i*

This announcement is made by CanSino Biologics Inc. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that the National Medical Products Administration (the "**NMPA**") of China has granted new drug application (the "**NDA**") approval to the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (the "**PCV13*i***") developed by the Company.

The Company's PCV13*i* adopts a covalent combination of polysaccharide antigens and carrier proteins. After the polysaccharide antigens are linked to the carrier proteins, the polysaccharide can be converted into T cells dependent antigens, which not only induces a high level of specific antibodies in infants and young children under 2 years old, but also generates memory B cells to produce immune memory. Meanwhile, the Company adopts dual vector technology which can reduce the immunosuppression to immunogenicity when co-injecting with other vaccines. In terms of production technology, the Company has adopted a safer production process, with animal-free culture medium as the fermentation medium, reducing risks from animal-derived biological factors and avoiding the toxicity residue from traditional purification process by phenol method.

PCV13*i* is the first product in the Company's pneumococcal vaccine portfolio that has obtained NDA approval, laying a foundation for the development of higher-valent pneumococcal conjugate vaccines. Meanwhile, as PCV13*i* has a similar market positioning to the Company's current major commercialized product, Menhycia®, the MCV4 vaccine positioned by the Company as a high-end self-paid vaccine, the two products' target consumer groups overlap. The launch of PCV13*i* will enrich the Company's commercialized product portfolio and enhance its marketing efficiency.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, June 20, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.